Allogene Therapeutics, Inc.
allogene.comWhat Do They Do?
Develops off-the-shelf, donor-derived engineered T-cell candidates for treating cancer and autoimmune diseases.
10-K for FY2025, filed Mar 12, 2026OverviewView ↗
We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates…View ↗
We are currently developing a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing…View ↗
Who Are Their Customers?
Revenue comes from collaboration and licensing partners, including Servier; they contract with Allogene for licenses, research and development work, and product supply.
10-K for FY2025, filed Mar 12, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$42.7MView ↗
- ▼ −16% (Loss)
- vs −$50.9M in Q2 FY2025
-
Sep 2, 2026
CFO Geoffrey Parker announced his retirement
His retirement from all company roles is effective November 6, 2026.
Sources
8-K, filed Sep 2, 2026
On August 31, 2026, Geoffrey Parker, the Executive Vice President and Chief Financial Officer and principal financial officer of Allogene…View ↗
-
May 28, 2026
Zachary Roberts replaced David Chang as CEO
Roberts became CEO on July 1, 2026; Chang remained on the board.
Sources
8-K, filed May 28, 2026
On May 28, 2026, the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its…View ↗
-
May 13, 2026
Allogene ended Overland’s exclusive license for cell therapy targets
The license covered development, manufacturing and sales rights for four targets across Greater China, Taiwan, South Korea and Singapore.
Sources
8-K, filed May 13, 2026
Pursuant to the Termination Agreement, the parties agreed to terminate that certain Exclusive License Agreement, dated December 14, 2020…View ↗
-
Apr 13, 2026
Interim trial data showed more patients cleared minimal residual disease with cema-cel
Minimal residual disease was cleared in 58.3% of the cema-cel arm versus 16.7% of the observation arm.
Sources
8-K, filed Apr 13, 2026
At the protocol-defined data cutoff date, 58.3% (7/12) of patients in the cema-cel arm achieved MRD negativity compared to 16.7% (2/12) in…View ↗
Who Do They Compete With?
Competes with Novartis, Kite, Bristol-Myers Squibb, Autolus Therapeutics, AstraZeneca, Atara Biotherapeutics, Beam Therapeutics, Caribou Biosciences, CRISPR Therapeutics, Editas Medicine, Fate Therapeutics, Gilead Sciences, Imugene, Intellia Therapeutics, Legend Biotech, Precision Biosciences, and Sana Biotechnology
10-K for FY2025, filed Mar 12, 2026Autologous T cell therapies directed at CD19 have been commercialized by Novartis, Kite/Gilead and Bristol-Myers Squibb Company (BMS) and…View ↗
Loading...
